An Open-label, Dose Escalation Safety and Tolerability Study of Recombinant Human Interleukin-21 (Phase 1) Followed by an Open-label Treatment Study (Phase 2a) in Patients With Stage IV Malignant Melanoma
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2016
At a glance
- Drugs Denenicokin (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 01 Jul 2009 Actual end date (Oct 2007), actual number of patients (54) added as reported by ClinicalTrials.gov.
- 11 Dec 2007 Status change from in progress to recruiting.
- 15 Aug 2007 Status changed from recuiting to in progress.